Crexont (Carbidopa and Levodopa) for Parkinson's Disease

Overview
Crexont is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson’s disease, post-encephalitic parkinsonism (Parkinson-like symptoms following brain inflammation), and parkinsonism that may occur after carbon monoxide or manganese intoxication in adults. Crexont is typically prescribed to people who require treatment for the symptoms of Parkinson’s disease or similar conditions caused by other factors. Crexont is also known by its drug names, carbidopa and levodopa.

Crexont is a combination of two drugs. Carbidopa prevents the breakdown of levodopa before it reaches the brain, where levodopa is then converted into dopamine — a neurotransmitter (brain chemical) that plays a role in movement, mood, motivation, and reward — that is deficient in people with Parkinson’s disease. This increase in dopamine levels helps to reduce symptoms such as tremors, stiffness, and difficulty moving.

How do I take it?
Prescribing information states that Crexont should be taken orally as extended-release capsules. Individuals who have never taken levodopa generally start with lower doses taken twice daily for the first three days. Starting on the fourth day, the dosage may be gradually increased as needed. For those switching from immediate-release carbidopa/levodopa, the dosing schedule varies. Crexont may be taken with or without food but should not be chewed, divided, or crushed. It is important to avoid alcohol while taking Crexont. The medication should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Crexont include nausea and anxiety.

Rare but serious side effects may include falling asleep during daily activities; withdrawal-emergent hyperpyrexia (a rapid and dangerous rise in body temperature) and confusion if the drug is suddenly discontinued or reduced; cardiovascular events (especially in those with a history of heart disease); hallucinations or psychosis; impulse control disorders (such as compulsive behaviors); and worsening of dyskinesia (involuntary movements).

For more information about this treatment, visit:

Label: Crexont — Carbidopa and Levodopa Capsule, Extended Release — DailyMed

Crexont — Drugs.com